GLP-1 receptor agonists and GLP-1/GIP co-agonists do not appear to increase pancreatitis risk, though DPP-4 inhibitors may carry a small risk, and gallbladder problems are more common with GLP-1 drugs.
No increased pancreatitis riskMeta-analyses of long-term trials found no association between GLP-1 receptor agonists and acute pancreatitis
What the researchers found
Meta-analyses of long-term randomized controlled trials show DPP-4 inhibitors carry a small increased risk of acute pancreatitis, but GLP-1 receptor agonists and GLP-1/GIP co-agonists do not. GLP-1 receptor agonists and co-agonists are associated with higher rates of cholecystitis and cholelithiasis (gallbladder inflammation and gallstones). No incretin-based drug class is associated with increased pancreatic cancer risk.
Why it matters
With GLP-1 drugs now prescribed to millions for diabetes and obesity, safety concerns about pancreatitis have been a persistent worry. This review provides reassurance that GLP-1 receptor agonists themselves don't raise pancreatitis risk, though it flags gallbladder issues as a real concern clinicians should monitor.
The numbers in context
- DPP-4 inhibitors: small increased risk of acute pancreatitis in meta-analyses
- GLP-1 receptor agonists: no increased risk of acute pancreatitis
- GIP/GLP-1 co-agonists: no increased risk of acute pancreatitis
- GLP-1 drugs and co-agonists: higher rates of cholecystitis and cholelithiasis
- None of the drug classes linked to pancreatic cancer
How the study worked
Narrative review synthesizing evidence from individual randomized controlled trials and meta-analyses of long-term trial data for DPP-4 inhibitors, GLP-1 receptor agonists, and GLP-1/GIP co-agonists.
Who was studied
General review of patients with type 2 diabetes and obesity using incretin-based therapies
What this study cannot tell us
Narrative review without systematic methodology. Individual trials were often underpowered to detect rare events like pancreatitis. Observational data on gallbladder risk may be confounded by weight loss itself, which is a known gallstone risk factor.
How to read the evidence
Rated strong: synthesizes multiple meta-analyses of large randomized controlled trials, providing robust evidence on the pancreatitis question.
When this study was published
Published in 2024, incorporating the most recent meta-analyses and trial data for all major incretin drug classes including newer co-agonists.
The bigger picture
As GLP-1 drugs expand beyond diabetes into obesity treatment, understanding their gastrointestinal safety profile is critical. The pancreatitis concern appears largely unfounded for GLP-1 receptor agonists, but gallbladder complications deserve clinical attention.
Questions still open
- Is the gallbladder risk from GLP-1 drugs driven by rapid weight loss rather than the drug itself?
- Should patients with a history of gallbladder disease avoid GLP-1 therapy?
- Will longer-term post-marketing surveillance change the pancreatitis risk assessment?
Common questions
Can Ozempic or other GLP-1 drugs cause pancreatitis?
Do GLP-1 drugs cause gallbladder problems?
Read the original research
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?
Current opinion in gastroenterology, 40(5), 404-412
Citation
Pratley, Richard; Saeed, Zeb I; Casu, Anna. (2024). Incretin mimetics and acute pancreatitis: enemy or innocent bystander?. Current opinion in gastroenterology, 40(5), 404-412. https://doi.org/10.1097/MOG.0000000000001057